Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer (IPSO)

IPSO Trial - Impact of Parental Support on Pregnancy Outcomes: A Multi-Center, Randomized, Open-Label Study to Evaluate the Implantation and Pregnancy Rates Following 24 Chromosome Aneuploidy Screening With Parental Support in Patients Undergoing In Vitro Fertilization (IVF)

Natera is recruiting patients for a research study evaluating pregnancy and implantation rates in women undergoing In Vitro Fertilization (IVF) and Preimplantation Genetic Screening (PGS). PGS is also referred to as Preimplantation Genetic Diagnosis (PGD) for aneuploidy.

Healthy women undergoing IVF who are between the ages of 35 to 42 years are being recruited to participate in a randomized study.

The purpose of this study is to determine whether PGS- testing of embryos created during IVF for chromosomal abnormalities, prior to transfer to the uterus- improves pregnancy and implantation rates in patients when compared to patients whose embryos are not tested. PGS will be conducted using 24 Chromosome Aneuploidy Screening with Parental Support from Natera.

All subjects who qualify and enroll will receive discounted IVF medications (both TEST and CONTROL arms). If you become pregnant during the study, you will receive a small payment for providing information about your pregnancy and birth. If you are assigned to the TEST arm of the study you will receive free PGS.

Study Overview

• Status: Terminated
• Conditions: In Vitro Fertilization (IVF); Preimplantation Genetic Diagnosis (PGD); Preimplantation Gentic Screening (PGS)
• Intervention / Treatment: Device: 24 Chromosome Aneuploidy Screening with Parental Support

Detailed Description

If you meet the criteria below, you may be a candidate for this study. To participate in the study you must:

• Be a healthy, pre-menopausal female, 35-42 years of age
• Have a history of less than 3 consecutive miscarriages and no more than one failed IVF cycle
• Agree to use Ferring Pharmaceutical products during stimulation
• Agree to be randomly assigned to either the arm of the study receiving PGS (TEST arm)or the arm receiving no additional testing (CONTROL arm)

Additional screening will be conducted to determine if you are eligible to enroll.

All subjects who qualify and enroll will receive discounted IVF medications. If you become pregnant during the study, you will receive a small payment for providing information about your pregnancy and birth. If you are assigned to the TEST arm of the study you will receive free PGS.

• Study Type: Interventional
• Enrollment (Actual): 59
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • Laguna Hills, California, United States, 92653
      • Huntington Reproductive Center
  • District of Columbia
    • Washington, District of Columbia, United States, 20006
      • Shady Grove Fertility RSC
  • Florida
    • Clearwater, Florida, United States, 33759
      • Florida Fertility Institute/ Women's Medical Research Group, LLC
  • Georgia
    • Atlanta, Georgia, United States, 30328
      • Atlanta Center for Reproductive Medicine
  • Illinois
    • Chicago, Illinois, United States, 60610
      • Fertility Centers of Illinois
  • Massachusetts
    • Boston, Massachusetts, United States, 02451
      • Boston IVF
  • Nevada
    • Reno, Nevada, United States, 89511
      • The Nevada Center for Reproductive Medicine
  • Pennsylvania
    • Bryn Mawr, Pennsylvania, United States, 19010-3121
      • Main Line Fertility
  • Texas
    • Houston, Texas, United States, 77054
      • Fertility Specialist of Houston

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 42 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Must agree to a follow-up visit at approximately 4-8 weeks gestation and a follow up phone call at 20 and 40 weeks gestation/livebirth. For patients assigned to the TEST group must agree to PGD testing and collection of buccal swab sample on newborn
• At least 10 eggs retrieved
• Must agree to use only Ferring products during stimulation
• Normal uterine cavity detected on hysterosalpingogram (HSG), saline infusion sonogram (SIS), or hysteroscopy
• Signed consent form

Exclusion Criteria:

• FSH ≥10 IU/L within past year prior to screening
• 2 or more previously failed IVF cycles
• Gestational or surrogate carrier, donor oocyte, donor sperm
• History of recurrent pregnancy loss (3 or more consecutive miscarriages)
• Severe male factor infertility defined as ejaculate sperm of < 1million sperm/ml, or sperm obtained through testicular biopsy
• Gender selection as primary indication
• Maternal disease that is not clinically stable and known to impact the ability to become pregnant or carry a pregnancy to term (lupus, chronic liver or kidney disease, body mass index (BMI) >35, uncontrolled hypertension, anti-phospholipid antibody, thrombophilia, insulin dependent diabetes)
• Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests
• Participation in any experimental drug study within 30 days prior to Screening
• Prior hypersensitivity to any of the protocol drugs
• Known history conveying increased risk for chromosome abnormality (beyond maternal age) or genetic disease in offspring

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: CONTROL arm; Subjects assigned to this arm of the study will receive no PGS testing.
Other: TEST arm; Subjects assigned to this arm of the study will receive PGS testing.	Device: 24 Chromosome Aneuploidy Screening with Parental Support; Preimplantation Genetic Screening (PGS); Other Names: Preimplantation Genetic Diagnosis (PGD)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implantation Rate	Implantation rate is defined as the ratio between the number of gestational sacs with a fetal heartbeat and the total number of embryos transferred.	Data is collected at approximately 4-6 weeks gestation, 20 weeks gestation and 40 weeks gestation.

Collaborators and Investigators

• Sponsor: Natera, Inc.
• Collaborators: Ferring Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: September 1, 2010
• Primary Completion (Actual): April 1, 2013
• Study Completion (Actual): April 1, 2013

Study Registration Dates

• First Submitted: August 2, 2010
• First Submitted That Met QC Criteria: September 1, 2010
• First Posted (Estimate): September 3, 2010

Study Record Updates

• Last Update Posted (Estimate): November 25, 2014
• Last Update Submitted That Met QC Criteria: November 12, 2014
• Last Verified: November 1, 2014

More Information

Terms related to this study

• Keywords: IVF; In Vitro Fertilization; PGD; PGS; Preimplantation Genetic Diagnosis; Preimplantation Gentic Screening
• Additional Relevant MeSH Terms: Pathologic Processes; Disease
• Other Study ID Numbers: IVF006-D3